Park Medi World Q1 FY26 Results (NSE: PARKHOSPS)
Signal: Margin expansion
The read
Margin trajectory strong (4th straight expansion), but bottom-line growth impaired by dilution and rising capex/finance costs; acquisition-led growth strategy accelerates, adding ~1,500 beds over 12 months.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹460 Cr | 32.2% | 0% |
| EBIT | ₹129 Cr | 31.6% | |
| Net profit | ₹77 Cr | 48.1% | |
| EPS | ₹1.64 | -44.8% | |
| EBIT margin | 28% |
P&L walk
Revenue growth steady (+32% YoY), OPM expanded 400bps YoY to 28% (likely operating leverage + pricing/mix), but PAT flat sequentially as depreciation/finance costs absorbed gains.
Key positives
- Revenue ₹460 Cr, +32.2% YoY — growth sustained above 30%
- OPM 28%, +400bps YoY — 4th consecutive quarter of margin expansion, indicating operating leverage + pricing power
- Robust bed addition pipeline: ~1,500 beds to be added in 12 months (46% capacity expansion over Dec 2025 base)
- Acquisition of Mehar Hospital (150 beds, ₹107 Cr) strengthens Tricity cluster; accretive post-integration
Key concerns
- EPS ₹1.64 declined -44.8% YoY despite PAT growth — equity dilution hurting per-share value
- PAT ₹77 Cr flat QoQ — elevated depreciation/finance costs absorbing OPM gains
- P/E 48.97x at current price — valuation already prices in aggressive expansion; execution risk high
- Acquisition pipeline of ₹107 Cr + ongoing capex may strain balance sheet; no debt disclosure in this filing
Research and educational content only. Not investment advice.